GNC 083
Alternative Names: GNC-083Latest Information Update: 10 Oct 2024
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Sep 2024 Preclinical trials in Solid tumours in China (Parenteral) (Sichuan Biokin Pharmaceuticals pipeline, September 2024)